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ABSTRACT
Objective: Identifying individuals with high risk of type
2 diabetes is important. To evaluate discriminatory
ability of multiple biomarkers for type 2 diabetes in
a Chinese population.
Methods: Plasma adiponectin, plasminogen activator
inhibitor-1, retinol-binding protein 4, resistin,
C-reactive protein, interleukin 6 (IL-6), tumour
necrosis factor a receptor 2 and ferritin were
measured in a population-based sample of 3189
Chinese (1419 men and 1770 women) aged
50e70 years. A weighted biomarkers risk score (BRS)
was developed based on the strength of associations
of these biomarkers with type 2 diabetes. The
discriminatory ability was tested by the area under
receiver operating characteristics curve (AUC).
Results: Adiponectin, plasminogen activator inhibitor-
1, IL-6 and ferritin were independently associated with
the prevalence of type 2 diabetes, and they were used
to calculate the biomarkers risk score (BRS). After
adjustment for the confounding factors, the ORs for
type 2 diabetes and impaired fasting glucose with each
point increment of BRS were 1.28 (95% CI 1.22 to
1.34) and 1.16 (1.12 to 1.20), respectively. Compared
with those in the lowest quintile of the BRS, the
participants in the highest quintile have an OR (95%
CI) of 6.67 (4.21 to 10.55) for type 2 diabetes. The
area under the curve for the BRS and conventional risk
factors alone was 0.73 and 0.76, respectively, and
substantially increased to 0.81 after combining both
BRS and conventional risk factors (p<0.001).
Conclusions: These data suggest that combining
multiple biomarkers and conventional risk factors
might substantially enhance the ability to identify
individuals with type 2 diabetes. More prospective data
are warranted to conﬁrm this observation.
INTRODUCTION
In parallel with rapid nutritional and lifestyle
changes, such as an increased energy-dense
diet and reduced physical activity, the preva-
lence of type 2 diabetes has reached
epidemic level and currently affects 92.4
million (9.7%) Chinese adults.
1 About two-
thirds of these patients had previously
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ARTICLE SUMMARY
Article focus
- Development of type 2 diabetes could be delayed
or even prevented by lifestyle modiﬁcation.
Identifying individuals with high risk of type 2
diabetes is important.
- This study evaluated the discriminatory ability of
multiple biomarkers for type 2 diabetes in
a Chinese population.
Key messages
- Plasma adiponectin, plasminogen activator inhib-
itor-1, retinol-binding protein 4, resistin, C
reactive protein, interleukin 6, tumour necrosis
factor-a receptor 2 and ferritin were measured in
a population-based sample of 3189 Chinese. A
weighted biomarkers risk score (BRS) was
developed based on the strength of associations
of these biomarkers with type 2 diabetes.
- After adjustment for the confounding factors, the
OR for type 2 diabetes with each point increment
of BRS was 1.28 (95% CI 1.22 to 1.34). The area
under the curve for the BRS and conventional
risk factors alone was 0.73 and 0.76, respec-
tively, and substantially increased to 0.81 after
combining both BRS and conventional risk
factors (p<0.001).
- These ﬁnding suggested that combining multiple
biomarkers and conventional risk factors might
substantially enhance the ability to identify
individuals with type 2 diabetes.
Strengths and limitations of this study
- This is the ﬁrst study simultaneously assessing
the discriminatory ability of multiple biomarkers
together with conventional risk factors for type 2
diabetes in a large population-based sample from
the north and south of China.
- Limitations including, the cross-sectional nature
of the study, did not allow determination of the
extent to which diabetes incidence would be
predicted by the BRS; fasting glucose was
measured only once. The oral glucose tolerance
test, which was time-consuming and labour
intensive, was not performed in such a large
population.
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2 Poor control of diabetes will lead
to development of severe complications and substantially
increase medical and socioeconomic burdens.
2
Compelling evidence has indicated that onset of type 2
diabetes could be delayed or even prevented by lifestyle
modiﬁcation.
3 Thus, identifying individuals at high risk
at an early reversible stage of the disease is critical for
controlling the type 2 diabetes epidemic trend.
To predict or classify type 2 diabetes, several scoring
systems have been developed based on lifestyle
factors,
4e7 anthropometric markers
4e6 or genetic
factors.
8e10 Type 2 diabetes is a multifactorial disease,
and its pathogenesis involves dysregulation of various
biological pathways as well as an unfavourable proﬁle of
multiple cytokines such as adiponectin, plasminogen
activator inhibitor-1 (PAI-1), C-reactive protein (CRP)
and interleukin 6 (IL-6) in these pathways.
11 However,
most studies have focused on the effect of a single
cytokine on the risk of diabetes and few have investigated
the collective effect of these biomarkers together with
traditional risk factors in predicting the development of
type 2 diabetes.
12 In a recent report based upon the
ﬁnding from a subset population of the Inter99 Cohort,
a lifestyle intervention trial, a diabetes risk score
composed of adiponectin, CRP, ferritin, IL-2 receptor A,
glucose and insulin was shown to provide a better
predictive power for having type 2 diabetes than a single
variable among overweight Caucasian people.
13
However, little is known about whether these circulating
biomarkers might also be useful for predicting or
screening high-risk individuals among free-living
Chinese populations, who are considered to have
a higher susceptibility to metabolic disorders even within
‘low-risk’ range of inﬂammatory cytokine such as CRP
according to the criteria for Western populations.
14
Therefore, this study aimed to evaluate whether the
combination of eight plasma biomarkers, including
adiponectin, PAI-1, retinol-binding protein 4 (RBP4),
resistin, CRP, IL-6, tumour necrosis factor a receptor 2
(TNF-a-R2) and ferritin could improve the discrimina-
tory ability for type 2 diabetes individuals in middle-aged
and older Chinese men and women.
SUBJECTS AND METHODS
Study subjects
The study population included 3189 Shanghai and
Beijing residents aged 50e70 years from the Nutrition
and Health of Aging Population in China. This study was
conducted simultaneously both in Beijing and Shanghai
from March to June 2005. The participants were
recruited by a multistage sampling method. In each city,
two urban districts and one rural district were chosen to
represent different socioeconomic statuses. We planned
to select 400 participants from each urban district and
800 people from each rural district from the eligible
candidates listed in the residential registration record.
The eligibility of the candidates was deﬁned as those who
had been stable residents for at least 20 years in the
areas. Those with severe psychological disorders, physical
disabilities, cancer, cardiovascular disease, Alzheimer’s
disease, or currently diagnosed with tuberculosis, AIDS,
and other communicable diseases were excluded.
The study design and protocols have been described
elsewhere.
14 In brief, information on demographic
characteristics, health status, lifestyle practice and phys-
ical activity was collected using a standard questionnaire.
Body weight and height were measured and body mass
index (BMI) was calculated as weight (kg)/ height (m
2).
Overnight fasting plasma samples were collected and
stored at  808C until laboratory assays were performed.
The study protocol was approved by the institutional
review board of the Institute for Nutritional Sciences,
and all participants provided written informed consents.
A total of 3189 participants (1419 men and 1770 women)
with none of the eight selected biomarkers missing were
included in this study. Individuals were deﬁned as having
type 2 diabetes if they had a fasting glucose $7.0 mmol/
l, or previously diagnosed type 2 diabetes, or used
hypoglycaemic drugs including insulin. Impaired fasting
glucose (IFG) and normal fasting glucose (NFG) were
deﬁned as a participant with a fasting glucose level $5.6
to <7.0 mmol/l and <5.6 mmol/l, respectively.
Laboratory measurement
Plasma fasting glucose was measured enzymatically on an
automatic analyzer (Hitachi 7080, Japan) with reagents
from Wako Pure Chemical Industries (Osaka, Japan).
14
HbA1c was quantiﬁed from erythrocyte with automated
immunoassay (Roche Diagnostics, Indianapolis, Indiana,
USA).
14 Plasma adiponectin, PAI-1 and resistin concen-
trations were analysed by Luminex xMAP Technology on
a Bio-Rad Multiplex Suspension Array System with an
intra-assay coefﬁcient of variation (CV) of 1.4e7.9% and
an interassay CV<21%.
15 16 Circulating RBP4 was eval-
uated in duplicate by a sandwich ELISA kit developed in-
house, with an intra-assay CV of 1.8e7.6% and an inter-
assay CV of 3.7e8.8%.
17 Plasma high-sensitivity CRP was
measured by a particle-enhanced immunoturbidimetric
assay (Roche Diagnostics), and both intra-assay and
interassay CV of CRP levels were <12%.
14 IL-6 was
determined with a high-sensitivity ELISA (R&D Systems,
Inc, Minneapolis, Minnesota, USA), with both intra-assay
and interassay CVs <10%.
14 Soluble TNF-a-R2 was
detected with a Human Death Receptor 3-Plex kit
(Biosource International, Inc, Camarillo, California,
USA) through the Multiplex Suspension Array System.
the average intra-assay CV and interassay CVs for TNF-a-
R2 were 7.9% and 10.1%, respectively.
18 Plasma ferritin
was assayed using a commercially available particle-
enhanced immunoturbidimetric kit (Shanghai
Gensource Co, Ltd, Shanghai, China).
19 The intra-assay
CV of ferritin measurements was <2.0%, whereas the
interassay CV was <6.1%.
Statistical analyses
A multivariate logistic regression was applied to estimate
the ORs for individual biomarkers. Results for the
2 Wu H, Yu Z, Qi Q, et al. BMJ Open 2011;1:e000191. doi:10.1136/bmjopen-2011-000191
Multiple biomarkers on type 2 diabetesassociation for each single biomarker have been
reported elsewhere.
15 16 18 19 The corresponding b coef-
ﬁcients (log ORs) in logistic regression models were
employed to assign a score value for each biomarker;
only the biomarkers with p values <0.05 after including
all the eight biomarkers in the model with forward
selection were then selected in the scoring system. A
weighted biomarkers risk score (BRS) was developed
based on the assumption that selected biomarkers
have independent effects on type 2 diabetes and
also contribute to diabetes risk in an additive
manner.
20 Accordingly, adiponectin, PAI-1, IL-6 and
ferritin were used to compute a BRS which was derived
as the following equation: BRS¼k 3 (b1 3 biomar-
ker1+b2 3 biomarker2+.+bk 3 biomarkerk)/(b1+b2+.
+bk). Where k represents the number of the biomarkers
used (in this study k¼4), bί is the assigned sore value of
each biomarker corresponding to the log (OR) in
logistic regression, biomarkerί assigned to 0, 1, 2 or 3
according to low to high quartile of the speciﬁc
biomarker.
20 The quartiles of adiponectin were assigned
as 3, 2, 1 or 0, because of its inverse association with
diabetes risk. The confounding factors, which were
adjusted in the logistic regression models included age,
sex, geographical region (Shanghai or Beijing), resi-
dence (urban or rural), smoking status (ex-smoker,
current smoker and non-smoker), alcohol drinking (yes
or no), physical activity (low, moderate or high), family
history of diabetes (yes or no) and BMI. Area under the
receiver operator characteristic curve (AUC) was calcu-
lated to evaluate the ability of BRS and conventional risk
factors alone or collectively in discriminating the preva-
lence of type 2 diabetes. Net reclassiﬁcation improve-
ment (NRI) and integrated discrimination improvement
(IDI) statistics were also applied to test the discrimina-
tive ability.
21 The categories <10%, 10e20%, 20e35%
and >35% were used in the reclassiﬁcation analyses.
Analyses were performed using SAS V.9.2 (SAS Insti-
tute). All reported p values are two-sided and considered
statistically signiﬁcant for p<0.05.
RESULTS
The characteristics of the 3189 participants are presented
in table 1, the prevalence of type 2 diabetes and IFG were
13.6% (n¼434) and 26.9% (n¼858), respectively. As
expected, the participants with type 2 diabetes had lower
plasma adiponectin, but higher concentrations of RBP4,
PAI-1, CRP, IL-6 and ferritin than their IFG and NFG
Table 1 Characteristics of the study population*
Characteristics NFG IFG Type 2 diabetes
n (%) 1897 (59.5) 858 (26.9) 434 (13.6)
Age (years) 58.466.0 58.666.0 59.765.7
Men, n (%) 789 (41.6) 414 (48.3) 216 (49.8)
Beijing residents, n (%) 727 (38.3) 564 (65.7) 282 (65.0)
Urban residents, n (%) 931 (49.1) 402 (46.9) 254 (58.5)
BMI (kg/m
2) 23.863.5 25.463.6 25.463.5
Family history of diabetesy, n (%) 181 (9.5) 110 (12.8) 142 (32.7)
Smoking status, n (%)
Non-smoker 1230 (64.8) 484 (56.4) 263 (60.6)
Ex-smoker 152 (8.0) 111 (12.9) 61 (14.1)
Current smokers 515 (27.1) 263 (30.7) 110 (25.3)
Alcohol drinking, n (%) 470 (24.8) 302 (35.2) 133 (30.6)
Physical activity
Low 136 (7.2) 74 (8.6) 25 (5.8)
Moderate 817 (43.1) 324 (37.8) 198 (45.6)
High 944 (49.8) 460 (53.6) 211 (48.6)
Fasting glucose (mmol/l) 5.0660.36 6.0160.34 8.9463.02
Fasting insulin (pmol/l) 12.9 (9.4 17.5) 15.1 (11.1 20.4) 14.8 (10.3 22.4)
HbA1c (%) 5.6460.42 5.8560.45 7.8162.01
Adiponectin (mg/ml) 14.9 (9.0 23.3) 12.4 (7.6 20.6) 10.1 (5.5 17.2)
RBP4 (mg/ml) 39.1611.4 41.3612.2 41.3611.9
PAI-1 (ng/ml) 6.68 (2.25 15.4) 11.8 (4.45 23.8) 13.3 (5.5 25.6)
Resistin (mg/ml) 8.56 (5.67 13.9) 8.56 (5.92 14.4) 8.86 (6.03 13.7)
CRP (mg/l) 0.57 (0.30 1.27) 0.79 (0.36 1.76) 0.97 (0.46 2.37)
IL-6 (ng/l) 0.96 (0.62 1.48) 1.12 (0.72 1.65) 1.26 (0.81 1.89)
TNF-aR2 (mg/l) 1.62 (1.28 2.01) 1.61 (1.22 1.99) 1.64 (1.30 2.12)
Ferritin (g/l) 0.12 (0.08 0.17) 0.15 (0.10 0.20) 0.17 (0.12 0.24)
Biomarkers risk score 5.21 (3.40 7.18) 6.74 (4.77 8.60) 7.62 (5.86 9.26)
*Data are means6SD, medians (IQR) or n (%), unless otherwise indicated.
yFirst-degree relatives (parents or siblings) had a history of diabetes.
BMI, body mass index; CRP, C-reactive protein; IFG, impaired fasting glucose; IL, interleukin; NFG, normal fasting glucose; PAI-1, plasminogen
activator inhibitor-1; RBP4, retinol-binding protein 4; TNF-aR2, tumour necrosis factor a receptor 2.
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lower adiponectin and higher PAI-1, CRP, IL-6 and
ferritin (all p<0.001 for trend), but not with RBP4,
resistin or TNF-a-R2 levels (supplemental table 1 and
supplemental ﬁgure 1). Multiple logistic regression
analysis with forward selection included all of these eight
biomarkers in the model showed that adiponectin, PAI-1,
IL-6 and ferritin were signiﬁcantly and independently
associated with type 2 diabetes. Thus, these four
biomarkers were used to develop a weighed BRS.
Compared with NFG participants, the participants
with type 2 diabetes have signiﬁcantly higher level of
BRS (median (IQR): 7.62 (5.86e9.26) vs 5.21
(3.40e7.18), p<0.001, table 1). The distribution of BRS
was shifted right in diabetic individuals compared with
those with NFG (ﬁgure 1). After adjustment for age, sex,
region, residence, smoking, alcohol drinking, physical
activity, family history of diabetes and BMI, the ORs for
type 2 diabetes and IFG with each point increment of
B R Sw e r e1 . 2 8( 9 5 %C I1 . 2 2t o1 . 3 4 ;p <0.001) and 1.16
(95% CI 1.12 to 1.20; p<0.001), respectively (table 2).
Similar ORs were observed among both sexes (p for
interaction¼0.48 and 0.49 for diabetes and IFG,
respectively) and age groups deﬁned by the cut-off
point of 60 years (p for interaction¼0.38 and 0.49 for
diabetes and IFG, respectively). Among individuals with
a score >10 (7.4%), the ORs were 9.95 (95% CI 5.46 to
18.13) for type 2 diabetes and 3.96 (95% CI 2.57 to
6.10) for IFG compared with those with BRS #3.0
(14.86%) (ﬁgure 2). A similar association was also
found when the subjects were categorised into the BRS
quintiles (table 2). Compared with the lowest quintile
(BRS#3.5), the ORs in the highest quintile (BRS>8.5)
were 6.67 (95% CI 4.21 to 10.55) for type 2 diabetes and
3.09 (95% CI 2.29 to 4.19) for IFG after controlling for
the confounding factors.
The interaction between BRS and BMI on the preva-
lence of type 2 diabetes was also examined (supple-
mental ﬁgure 2). In multivariate analysis adjusted for
age, sex, region and residence, the odds of type 2 dia-
betes within each category of BMI increased signiﬁcantly
from the bottom to the top BRS quintile (p<0.0001 for
Figure 1 Percentage of participants in each biomarkers risk
score category among those who had normal fasting glucose
and type 2 diabetes. Risk of developing type 2 diabetes
according to biomarkers risk score is shown as a ﬁtted line
from regression analysis.
Table 2 Association of biomarkers risk score (BRS) and risk of type 2 diabetes and impaired fasting glucose (IFG)
Quintiles of BRS Continuous BRS
Variables Q1 Q2 Q3 Q4 Q5 OR (95% CI) p Value
N 637 642 629 648 633
Median
(range)
2.3
(0.0 to 3.5)
4.4
(3.6 to 5.2)
6.0
(5.2 to 6.7)
7.5
(6.8 to 8.5)
9.7
(8.5 to 12.0)
Risk of type 2 diabetes
Model 1* 1.0 1.45
(0.88 to 2.40)
3.29
(2.10 to 5.15)
4.19
(2.70 to 6.52)
6.45
(4.18 to 9.97)
1.27
(1.22 to 1.33)
<0.001
Model 2y 1.0 1.51
(0.91 to 2.50)
3.28
(2.08 to 5.18)
4.35
(2.77 to 6.81)
6.72
(4.32 to 10.45)
1.28
(1.22 to 1.34)
<0.001
Model 3z 1.0 1.51
(0.91 to 2.50)
3.27
(2.06 to 5.18)
4.32
(2.73 to 6.83)
6.67
(4.21 to 10.55)
1.28
(1.22 to 1.34)
<0.001
Risk of IFG
Model 1* 1.0 1.25
(0.94 to 1.66)
1.70
(1.28 to 2.25)
2.12
(1.60 to 2.80)
3.89
(2.92 to 5.19)
1.19
(1.15 to 1.24)
<0.001
Model 2y 1.0 1.25
(0.94 to 1.67)
1.69
(1.27 to 2.24)
2.13
(1.61 to 2.83)
3.94
(2.95 to 5.27)
1.20
(1.16 to 1.24)
<0.001
Model 3z 1.0 1.16
(0.87 to 1.55)
1.50
(1.13 to 2.00)
1.76
(1.31 to 2.35)
3.09
(2.29 to 4.19)
1.16
(1.12 to 1.20)
<0.001
Data are OR (95% CI).
*Model 1 adjusted for age, gender, region and residence.
yModel 2 further adjusted for smoking, alcohol drinking, physical activity and family history of diabetes.
zModel 3 further adjusted for body mass index.
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2)i nt h e
highest BRS quintile had an OR of 7.08 (95% CI 3.98 to
12.59) compared with their normal-weight counterparts
(BMI <24 kg/m
2) in the lowest quintile of BRS.
However, no signiﬁcant interaction was found between
BRS and BMI (p¼0.51 for interaction).
To explore the discriminatory ability of BRS, receiver
operator characteristic curve analyses were performed
(ﬁgure 3). The AUCs were 0.64, 0.64, 0.60 and 0.67 for
adiponectin, PAI-1, IL-6 and ferritin, respectively. The
AUCs were 0.73 (95% CI 0.71 to 0.76) for the BRS and
0.76 (95% CI 0.74 to 0.78) for conventional risk factors,
including age, sex, region, residence, smoking, alcohol
use, physical activity, family history of diabetes and BMI.
Adding BRS to conventional risk factors signiﬁcantly
improved the AUC to 0.81 (95% CI 0.79 to 0.84;
p<0.0001). Excluding the participants with previous
diagnosis of diabetes did not appropriately change the
identifying ability of BRS, with an increase of AUC from
0.74 (95% CI 0.71 to 0.78) to 0.82 (95% CI 0.80 to 0.85;
p<0.0001) after combining the BRS with conventional
risk factors. On the other hand, adding the BRS into the
model signiﬁcantly improved the IDI (IDI¼0.0669,
p<0.0001). The NRI was estimated at 25.7% (p<0.0001),
resulting from a total of 16.7% of cases classiﬁed
upwards and a total of 9.0% of no cases classiﬁed
downwards (table 3). If the cut off points <3%, 3%e8%,
8%e15% and >15% were used as in previous study,
22
the NRI was increased to 33.1% (p<0.0001).
DISCUSSION
In this study, we showed that a weighted BRS, summa-
rising association of adiponectin, PAI-1, IL-6 and ferritin,
was strongly associated with type 2 diabetes and IFG in
a middle-aged and older Chinese population. The BRS
substantially improved the discriminatory ability for type
2 diabetes beyond conventional risk factors.
Since lifestyle modiﬁcation has been demonstrated to
be effective in prevention of type 2 diabetes, several
prediction models have been developed to detect high-
risk individuals among apparently healthy people for
early intervention. However, most of the previous scoring
systems for early screening of type 2 diabetes were based
on the risk factors related to demographic,
4 6 lifestyle,
467
anthropometric
4e6 or genetic parameters.
81 0Addition-
ally, most of these systems were derived from white
populations. Until now no diabetes risk evaluation
system has been developed for use in Asian populations,
especially in Chinese people who have a lower than
Figure 2 Risk of type 2 diabetes (A) and impaired fasting
glucose (IFG) (B) in each biomarkers risk score category after
adjustment for age, sex, region, residence, smoking, alcohol
drinking, physical activity, family history of diabetes and body
mass index.
Figure 3 Receiver operating characteristic curves for
discriminating type 2 diabetes. Graphs show curves for
biomarkers risk score alone (area under curve (AUC)¼0.73,
95% CI 0.71 to 0.76), for conventional risk factors including
age, sex, region, residence, smoking, alcohol use, physical
activity, family history of diabetes and body mass index
(AUC¼0.76, 95% CI 0.74 to 0.78) and for biomarkers
incorporated into conventional ones (AUC¼0.81, 95% CI 0.79
to 0.83).
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diabetes than Western populations.
23 In a cross-sectional
sample of Taiwanese subjects, Lin et al compared the
type 2 diabetes discriminatory power of 10 scoring
systems such as QDScore, FINDRISC, ARIC and the
Cambridge Risk Score derived from information
obtained from questionnaire and physical examination
without laboratory blood assays. It was found that all of
these scores improved the ability to detect type 2 dia-
betes, with an AUC ranging from 0.67 to 0.74.
24
In this middle-aged and older Chinese population, our
data showed that a BRS based on the combined effect of
adiponectin, PAI-1, IL-6 and ferritin, was closely associ-
ated with the prevalence of type 2 diabetes indepen-
dently of conventional diabetes risk factors. The
participants with a BRS>10 had about 10-fold increased
risk of type 2 diabetes than those with BRS#3.0. Both the
BRS and conventional risk factors alone showed
a reasonably good ability to distinguish individuals with
type 2 diabetes, with AUCs of 0.73 and 0.76, respectively.
More importantly, combining the BRS with conventional
risk factors substantially enhanced the discriminatory
ability for type 2 diabetes by increasing AUC to 0.81.
Moreover, adding BRS into the model signiﬁcantly
improved the IDI and NRI. Similarly, in FINRISK97
cohort study, a score calculated as a linear combination
of adiponectin, apolipoprotein B, CRP and ferritin was
showed to improve the net reclassiﬁcation and discrim-
ination of diabetes risk in addition to the traditional risk
factors.
22 Taken together, these ﬁndings emphasise that
combining multiple circulating biomarkers might
provide an additional objective tool in estimating the
diabetes risk beyond the conventional risk assessments in
clinical practice. These results might lead to use of these
biomarkers in practice to assess diabetes risk, and beneﬁt
those individuals at high risk by allowing early preventive
intervention. Nevertheless, more studies especially
prospective studies are needed to verify these ﬁndings.
Unlike previous studies,
12 which emphasised indi-
vidual biomarkers, we performed a combined analysis of
multiple biomarkers related to different pathogenesis
pathways of type 2 diabetes. A number of biomarkers
secreted by adipose tissue or liver play important roles in
the aetiology of type 2 diabetes via pathways which may
not be greatly overlapping.
11 For instance, adiponectin is
known to be an anti-inﬂammatory cytokine. However,
a strong association between high circulating adipo-
nectin levels and a lower risk of type 2 diabetes was
found even after adjustment for inﬂammatory
markers.
25 Indeed, adiponectin could also enhance lipid
clearance, and stimulate insulin secretion.
26 The link
between IL-6 levels and type 2 diabetes incidence in
several prospective studies, however, was mainly through
an inﬂammatory reaction that might modify glucose and
lipid metabolism.
27e29 On the other hand, elevated PAI-
1 concentration, a marker of endothelial dysfunction,
was also an independent predictor of incident dia-
betes.
30 31 As an indicator of iron overload, which might
result in b-cell oxidative stress, high circulating ferritin
was established as a risk factor for type 2 diabetes.
32 33
Consistent with previous studies,
23e31 plasma adipo-
nectin, PAI-1, IL-6 and ferritin in our study were inde-
pendently associated with the risk of diabetes. As each of
these biomarkers may involve one or more speciﬁc
pathways in the link with type 2 diabetes, it was not
surprising to ﬁnd a low value of the AUC for each
separate biomarker in discriminating diabetes individ-
uals. However, adding any one of these biomarkers to
the conventional factors signiﬁcantly improved the
power of discriminating the participants with and
without type 2 diabetes. Moreover, each of these
biomarkers contributed independently and additively to
risk assessment, and with the combined information of
these biomarkers, the BRS appeared to provide much
stronger discriminative power. In addition, with the
advance of biomarker measurement technology, we can
simultaneously assess multiple biomarkers with one
blood sample; for example, adiponectin, resistin and
PAI-1 were measured simultaneously in our study. Thus,
the cost of testing these biomarkers has been reduced,
Table 3 Net reclassiﬁcation improvement due to the biomarkers risk score
Predicted risk without
biomarkers risk score Predicted risk with biomarkers risk score
Participants with type 2
diabetes (n¼434)
<10% 10e20% 20e35% >35% Up Down
<10% 18 (40.9) 22 (50.0) 4 (9.1) 0 (0)
10e20% 19 (16.2) 40 (34.2) 40 (34.2) 18 (15.4) 130 (30.0) 57 (13.1)
20e35% 3 (2.3) 17 (13.1) 64 (49.2) 46 (35.4)
>35% 0 (0) 5 (3.5) 13 (9.1) 125 (87.4)
Participants with NFG (n¼1897)
<10% 665 (84.8) 99 (12.6) 20 (2.6) 0 (0)
10e20% 264 (42.0) 233 (37.0) 119 (18.9) 13 (2.1) 316 (16.7) 486 (25.6)
20e35% 36 (11.3) 120 (37.5) 99 (30.9) 65 (20.3)
>35% 2 (1.2) 21 (12.8) 43 (26.2) 98 (59.8)
Results are shown as number (%)
Net reclassiﬁcation improvement: 25.7% (SE 0.012), p<0.0001.
NFG, normal fasting glucose.
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Multiple biomarkers on type 2 diabeteswhich makes it feasible to measure multiple biomarkers
in primary care or large populations in the future. On
the other hand, if we could prevent a person at high risk
from developing clinically overt diabetes by early detec-
tion and intervention, the overall healthcare cost would
be signiﬁcantly reduced. Therefore, joint analysis for
multiple potential predictors might be a potentially
useful method for diabetes screening.
As far as we know, this is the ﬁrst study to assess
simultaneously the discriminatory ability of multiple
biomarkers together with conventional risk factors for
type 2 diabetes in a large population-based sample from
the north and south of China. However, our study has
some limitations. First, The cross-sectional nature of the
study meant that we could not determine the extent to
which diabetes incidence would be predicted by the
BRS. Second, fasting glucose was measured only once.
The oral glucose tolerance test, which is time-consuming
and labour intensive, was not performed in such a large
population sample size. However, HbA1c, which reﬂects
long-term glycaemic control, was evaluated in the whole
population. Another limitation is that we could not
include more biomarkers involved in the pathophysi-
ology of type 2 diabetes owing to limited blood samples.
However, we have captured the well-established
biomarkers in the major pathways related to insulin
sensitivity, inﬂammation, endothelial function and
oxidative stress.
In summary, a BRS derived from four circulating
biomarkers, is strongly associated with the risk of type 2
diabetes. Combining the BRS and conventional risk
factors substantially enhanced the discriminatory ability
for the disease in middle-aged and older Chinese
population. Whether the BRS could be used as an
effective screening tool for diabetes needs to be veriﬁed
in future studies.
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